Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Ainara Soria et al.|The Lancet|2018Cited by 1.7k
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapySusan Furness, David I. Conway, Anne‐Marie Glenny et al.|Cochrane Database of Systematic Reviews|2011Cited by 183
Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck CancerAlona Zer, Lori J. Bernstein, Gregory R. Pond et al.|JAMA Otolaryngology–Head & Neck Surgery|2017Cited by 56